Three of the four major inhaler manufacturers have announced plans to cap patient copays for all their inhalers at $35 a month in recent weeks, in addition to lowering the list prices of some of those products.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Consider these names, each of which knocked it out of the park with their latest financial results and gave bullish forward guidance.
The post The 3 Most Compelling Stocks Now That the Q4 Earnings Dust Has Settled appeared first on InvestorPlace.
More From InvestorPlaceA major sex scandal has devastated the government in Northern Ireland.